Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;17(1):63-70.
doi: 10.1159/000514860. Epub 2021 Mar 29.

Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review

Anastasios Kyriazoglou  1 , Maria Kaparelou  1 , Georgios Goumas  2 , Michael Liontos  1 , Roubini Zakopoulou  1 , Eleni Zografos  3 , Anna Zygogianni  4 , Meletios Athanasios Dimopoulos  1 , Flora Zagouri  1
Affiliations

Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review

Anastasios Kyriazoglou et al. Breast Care (Basel). 2022 Feb.

Abstract

Introduction: The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data.

Methods: We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer.

Results: Twelve clinical trials and 2 case reports were identified in our study.

Conclusion: The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer.

Keywords: Breast cancer; Checkpoint inhibitor; Clinical trials; HER2-positive breast cancer; Immunotherapy; Systematic review.

PubMed Disclaimer

Conflict of interest statement

F.Z. has received honoraria from Roche, Novartis, and Lilly. M.A.D. has received honoraria and participates in advisory boards from TAKEDA, Janssen, BMS, Cellgene, and Amgen.

Figures

Fig. 1
Fig. 1
Schematic presentation of the research strategy.
See this image and copyright information in PMC

References

    1. https://seer.cancer.gov/statfacts/html/breast.html .
    1. https://gco.iarc.fr/ GLOBAL CANCER OBSERVATORY.
    1. Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Ann Oncol. 2017 Jan;28((1)):16–33. - PMC - PubMed
    1. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 Apr;15((4)):433–451. - PubMed
    1. Loi S. The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. Ann Oncol. 2019 Aug;30((8)):1183–1184. - PubMed

Publication types